Burning Rock Biotech Limited (BNR)

Market Cap	67.50M
Revenue (ttm)	72.83M
Net Income (ttm)	-60.95M
Shares Out	10.26M
EPS (ttm)	-5.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,762
Open	6.02
Previous Close	6.15
Day's Range	5.96 - 7.00
52-Week Range	2.62 - 9.99
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 31, 2024

About BNR

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorect...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 786
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR
• Website: https://www.brbiotech.com

Financial Performance

In 2023, Burning Rock Biotech's revenue was 537.44 million, a decrease of -4.58% compared to the previous year's 563.24 million. Losses were -653.69 million, -32.69% less than in 2022.

Financial numbers in CNY